Research programme: GABA A receptor agonists - Neurogen Corporation

Drug Profile

Research programme: GABA A receptor agonists - Neurogen Corporation

Alternative Names: NG2-83

Latest Information Update: 06 Jul 2010

Price : $50

At a glance

  • Originator Neurogen Corporation
  • Developer Ligand Pharmaceuticals
  • Class
  • Mechanism of Action GABA A alpha 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 06 Jul 2010 Development discontinued during 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top